患有的人群中肥胖和体力活动减少的高患病率:单中心横截面研究
Sue Ann Chang1, Juen Kiem Tan1, Muhammad Samir Haziq Abd Rahman2
1Department of Medicine, Faculty of Medicine, National University of Malaysia, Kuala Lumpur 56000, Malaysia; Department of Medicine, Hospital Canselor Tuanku Muhriz, Kuala Lumpur 56000, Malaysia.
Epilepsy & behavior : E&B
|October 7, 2025
概括
肥胖影响马来西亚近40%的患者,与年龄,体力活动减少和某些药物等因素有关. 早期的体重指数 (BMI) 评估对于治疗患者的肥胖症至关重要.
科学领域:
- 神经学 神经学
- 公共卫生 公共卫生
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 肥胖是管理中日益关注的一个问题,受各种因素的影响.
- 马来西亚面临着一个重大的公共卫生挑战,即肥胖率的上升.
- 了解肥胖的流行率和的驱动因素对于当地医疗保健策略至关重要.
研究的目的:
- 为了确定在马来西亚患有的成年人中肥胖的流行率.
- 为了确定与肥胖相关的社会人口统计学和临床因素.
主要方法:
- 在马来西亚的一家神经病诊所进行了横截面研究.
- 收集了社会人口统计,临床和体育活动数据.
- 身体质量指数 (BMI) 用于将参与者分为肥胖或非肥胖.
主要成果:
- 在166名患有的成年人中,有39.2%被归类为肥胖.
- 肥胖与年龄较大,发迟,托皮拉使用和体力活动水平较低相关.
- 在肥胖与年龄,发病年龄,托皮拉马特使用和轻度活动得分之间发现了弱的正相关性.
结论:
- 患有的马来西亚成年人中肥胖的患病率超过了普通人口的患病率.
- 的肥胖是多因素的,涉及减少体力活动,衰老和抗发作药物.
- 建议进行常规的BMI查,以早期识别和干预,以改善患者的治疗结果.
相关概念视频
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
Drug Dosing: Obese Patients
222
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
222


